Oct 18, 2024
In the ever-evolving world of liver disease, the shift from Nonalcoholic Steatohepatitis (NASH) to Metabolic Associated Steatotic Hepatitis (MASH) marks a revolutionary leap in our understanding and approach to treatment. This transition isn't merely a rebranding; it signifies a profound recognition of the intricat...
Read More...
Oct 09, 2024
Nonalcoholic steatohepatitis (NASH), also referred to as Metabolic Dysfunction-Associated Steatohepatitis (MASH), has rapidly become a significant contributor to liver disease in the United States. The NASH market is growing at a substantial rate, driven by the increasing prevalence of the condition. According to t...
Read More...
Intratumoral Cancer Therapy: A Potential Weapon To Fight the Battle Against Cancer
Aug 05, 2026
The Next Wave of Radioligand Therapies: 5 Candidates to Watch
Mar 20, 2026
Newsletter/Whitepaper